• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

    3/27/25 9:15:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVSA alert in real time by email

    KEY HIGHLIGHTS:

    • Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025.
      • Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative).
    • Obesity proof-of-concept studies with Inflammasome ASC Inhibitor IC 100 in diet-induced obesity (DIO) mouse models are planned to begin H1-2025.
    • Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects.
    • Preclinical study funded by The Michael J. Fox Foundation (MJFF) to evaluate the potential of IC 100 as a treatment for Parkinson's disease has been completed and a manuscript has been submitted for publication.
    • Invited MJFF grant request for funding a second IC 100 preclinical study in Parkinson's disease animal model submitted; response expected in June, 2025.
    • Raised approximately $6.6 million in 2024 and $2.0 million in Q1-2025.

    WESTON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, or "ZyVersa")), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2024, and provides business update.

    "We are pleased to announce that development of our renal and anti-inflammatory pipelines has progressed to value-building milestones that we expect to achieve over the next 12 months," stated Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO, and President. "Our first-in-human Phase 2a clinical study with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease is anticipated to begin enrolling patients in the first half of 2025. Likewise, we expect to initiate our first-in-human Phase 1 trial with Inflammasome ASC Inhibitor IC 100 in overweight healthy subjects in the first half of 2026. This trial will be supported by two IC 100 preclinical studies in diet-induced obesity mouse models, with an interim data read-out for the first study expected second half of 2025. We look forward to reporting our near-term data read-outs, and the anticipated value they will bring to our shareholders."

    PIPELINE UPDATE

    Cholesterol Efflux Mediator™ VAR 200

    Kidney Disease (Global Drug Market: $18 Billion in 2024; $30 Billion Projected by 2034)

    A phase 2a clinical trial in patients with DKD is expected to begin in the first half of 2025. The intent of the study is to obtain renal patient proof-of-concept for VAR 200 prior to initiating a larger phase 2a/b for VAR 200's lead indication, FSGS. The DKD study will evaluate VAR 200's safety and efficacy (% change in proteinuria from baseline to week 12) in eight patients with type 2 diabetes who have diabetic kidney disease, which will provide insights for developing the subsequent FSGS study. The DKD study will be conducted at two clinical research sites.

    Inflammasome ASC Inhibitor IC 100

    Inflammatory Diseases (Global Biologics Market: $105 Billion in 2024; $186 Billion Projected by 2034)

    Obesity with Metabolic Complications

    In preparation for filing an IND for IC 100, planned for second half of 2025, we will initiate two diet-induced obesity (DIO) mouse model studies, with the first planned to begin in H1-2025. The studies will evaluate the effects of IC 100 on body weight, body composition, and changes in metabolic and inflammatory parameters in comparison to semaglutide (study 1), and the effects of IC 100 administered concurrently with semaglutide on those same endpoints (study 2). We expect a preliminary read-out of study 1 by end of second half 2025.

    Following IND clearance, a phase 1 trial will be initiated with IC 100 in healthy overweight people (BMI: 27 – 30) to evaluate the safety of 3 different doses of IC 100, and to get a signal on the degree of weight loss that can be expected with each dose. Results are anticipated in the first half of 2026.

    Parkinson's Disease

    A manuscript highlighting data from preclinical research studies funded by MJFF and conducted by researchers at University of Miami Miller School of Medicine has been submitted and is under peer review. The studies assessed the potential of IC 100 to block the damaging neuroinflammation that induces neural degeneration in Parkinson's disease.

    Based on the promising preclinical results, the MJFF project team suggested that we apply for a second grant for further research. A grant request has been submitted to MJFF proposing funding to conduct proof-of-concept studies in established Parkinson's disease animal models. An MJFF response to the grant request is expected in June, 2025.

    Additional Indications

    In 2024, two IC 100 papers were published supporting additional indications.

    • Stroke-related cardiovascular disease: IC 100 protected against stroke-related cardiovascular injury and dysfunction in an animal model. IC 100 blocked AIM2 inflammasome activation and cell death (pyroptosis) in the heart and improved cardiac function, following a stroke.
    • Retinopathy of Prematurity: IC 100 restored retinal structure and function in a retinopathy of prematurity animal model. IC 100 suppressed retinal microglia activation by interfering with ASC speck formation, attenuating retinal inflammation, abnormal retinal vascularization, and retinal thinning, and it led to restored retinal function.

    YEAR END 2024 FINANCIAL RESULTS

    Net losses were approximately $9.4 million for the year ended December 31, 2024, with an improvement of approximately $88.9 million or 90.4% compared to a net loss of approximately $98.3 million for the year ended December 31, 2023. The higher net loss reported for 2023 was primarily due to the one-time impairment of in-process research and development and the one-time impairment of goodwill of approximately $81.4 million and $11.9 million, respectively.

    Based on its current operating plan, ZyVersa expects its cash of approximately $1.5 million as of December 31, 2024, will be sufficient to fund its operating expenses and capital expenditure requirements on a month-to-month basis. ZyVersa will need additional financing to support its continuing operations, pay its current liabilities, and to meet its stated milestones. ZyVersa will seek to fund its operations and clinical activity through public or private equity or debt financings or other sources, which may include government grants, collaborations with third parties or outstanding warrant exercises.

    Research and development expenses were approximately $1.8 million for the year ended December 31, 2024, a decrease of approximately $1.4 million or 44.5% from the year ended December 31, 2023. The decrease is primarily attributable to a decrease of $1.4 million in manufacturing and pre-clinical costs of IC 100 in order to conserve cash.

    General and administrative expenses were approximately $7.4 million for the year ended December 31, 2024, a decrease of approximately $3.9 million or 34.4% from the year ended December 31, 2023. The decrease is attributable to a $0.7 million decrease in professional fees related to changes in public auditors and legal counsel, a $1.1 million decrease due to the prior 2023 lock up share agreement entered into previously with members of Larkspur Health Acquisition Corp., a $0.6 million decrease in director and officer insurance costs, a $0.4 million decrease in registration delay fees, a $0.4 million decrease in stock-based compensation as a result of options becoming fully amortized in 2024, a $0.4 million decrease due to no employee bonus accrual in 2024, and a $0.1 million decrease in marketing costs.

    ABOUT ZYVERSA THERAPEUTICS, INC.

    ZyVersa (NASDAQ:ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit www.zyversa.com.

    CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

    Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management's intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc. ("ZyVersa") uses words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa's expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa's ability to obtain the funding necessary to advance the development of our product candidates; plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa's planned preclinical and clinical trials; the timing of the availability of data from ZyVersa's preclinical and clinical trials; the timing of any planned investigational new drug application; ZyVersa's plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa's product candidates; ZyVersa's commercialization, marketing and manufacturing capabilities and strategy; ZyVersa's ability to protect its intellectual property position; and ZyVersa's estimates regarding future revenue, expenses, capital requirements and need for additional financing.

    New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.

    CORPORATE, MEDIA, IR CONTACT

    Karen Cashmere

    Chief Commercial Officer

    [email protected]

    786-251-9641



    ZYVERSA THERAPEUTICS, INC.
    CONSOLIDATED BALANCE SHEETS
         
        December 31,
        2024   2023 
           
    Assets      
           
    Current Assets:    
     Cash  $1,530,924  $3,137,674 
     Prepaid expenses and other current assets 184,873   215,459 
      Total Current Assets 1,715,797   3,353,133 
    Equipment, net  -   6,933 
    In-process research and development 18,647,903   18,647,903 
    Vendor deposit  178,476   98,476 
    Deferred offering costs  57,238   - 
    Operating lease right-of-use asset -   7,839 
           
      Total Assets$20,599,414  $22,114,284 
           
    Liabilities and Stockholders' Equity   
           
    Current Liabilities:    
     Accounts payable $9,337,267  $8,431,583 
     Accrued expenses and other current liabilities 1,894,041   1,754,533 
     Operating lease liability -   8,656 
      Total Current Liabilities 11,231,308   10,194,772 
    Deferred tax liability  851,659   844,914 
      Total Liabilities 12,082,967   11,039,686 
           
           
           
    Stockholders' Equity:    
     Preferred stock, $0.0001 par value, 1,000,000 shares authorized:   
     Series A preferred stock, 8,635 shares designated, 50 shares issued   
     and outstanding as of December 31, 2024 and 2023 -   - 
     Series B preferred stock, 5,062 shares designated, 5,062 shares issued   
     and outstanding as of December 31, 2024 and 2023 1   1 
     Common stock, $0.0001 par value, 250,000,000 shares authorized;   
     2,508,198 and 405,212 shares issued at December 31, 2024 and 2023,   
     respectively, and 2,508,191 and 402,205 shares outstanding as of   
     December 31, 2024 and 2023 250   40 
     Additional paid-in-capital 121,155,923   114,300,849 
     Accumulated deficit (112,632,559)  (103,219,124)
     Treasury stock, at cost, 7 shares at December 31, 2024 and 2023 (7,168)  (7,168)
      Total Stockholders' Equity 8,516,447   11,074,598 
           
      Total Liabilities and Stockholders' Equity$20,599,414  $22,114,284 
           



    ZYVERSA THERAPEUTICS, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS
     
       For the Year Ended
       December 31,
        2024   2023 
    Operating Expenses:   
     Research and development$1,779,275  $3,207,573 
     General and administrative 7,357,559   11,213,201 
     Impairment of in-process research and development -   81,438,426 
     Impairment of goodwill -   11,895,033 
      Total Operating Expenses 9,136,834   107,754,233 
          
      Loss From Operations (9,136,834)  (107,754,233)
          
    Other (Income) Expense:   
     Interest (income) expense 269,856   (457)
          
      Pre-Tax Loss  (9,406,690)  (107,753,776)
      Income tax (provision) benefit (6,745)  9,455,830 
      Net Loss  (9,413,435)  (98,297,946)
      Deemed dividend to preferred stockholders -   (7,948,209)
      Net Loss Attributable to Common Stockholders$(9,413,435) $(106,246,155)
          
          
      Net Loss Per Share   
      - Basic and Diluted$(8.48) $(1,089.70)
          
      Weighted Average Number of   
      Common Shares Outstanding   
      - Basic and Diluted 1,110,033   97,500 
          


    Primary Logo

    Get the next $ZVSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZVSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

      KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects at risk of cardiometabolic diseases.Groundbreaking data demonstrating IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation — bot

      5/12/25 4:35:00 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

      WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC Inhibitor IC 100. CEO Stephen C. Glover issued a shareholder letter detailing the company's strategy to position IC 100 as a complementary therapy to GLP-1 agonists to treat obesity-associated cardiometabolic complications. Obesity: A Global Health Crisis with Unmet Medical Needs Obesity has reached pandemic proportions, affecting over 40% of Americans, with a projected increase to 51% of the global population within 12 years

      5/7/25 7:57:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative). Obesity proof-of-concept studies with Inflammasome ASC Inhibitor IC 100 in diet-induced obesity (DIO) mouse models are planned to begin H1-2025.Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation

      3/27/25 9:15:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    SEC Filings

    See more
    • SEC Form 10-Q filed by ZyVersa Therapeutics Inc.

      10-Q - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

      5/12/25 4:37:07 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ZyVersa Therapeutics Inc.

      DEFA14A - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

      4/17/25 4:31:13 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by ZyVersa Therapeutics Inc.

      DEF 14A - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

      4/17/25 4:30:27 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Freitag Gregory Gene

      4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

      7/18/24 9:35:08 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Finizio Robert G

      4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

      7/18/24 9:35:05 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Glover Stephen C.

      4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

      7/18/24 9:35:11 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    Financials

    Live finance-specific insights

    See more
    • ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

      KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects at risk of cardiometabolic diseases.Groundbreaking data demonstrating IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation — bot

      5/12/25 4:35:00 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative). Obesity proof-of-concept studies with Inflammasome ASC Inhibitor IC 100 in diet-induced obesity (DIO) mouse models are planned to begin H1-2025.Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation

      3/27/25 9:15:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

      KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.Two obesity proof-of-concept studies with IC 100 in diet-induced obesity (DIO) mouse models are planned, which will include assessment of various metabolic parameters. At least one of the studies is targeted to begin Q4-2024.IC 100 Investigational New Drug (IND) submission is planned for Q2-2025, and once cleared, will be followed by

      11/14/24 8:10:00 AM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

      SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

      11/14/24 6:01:27 PM ET
      $ZVSA
      Biotechnology: Pharmaceutical Preparations
      Health Care